12 Health Care Stocks Moving In Monday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Monday's pre-market session, several healthcare stocks showed significant movement. Quoin Pharmaceuticals, Ainos, and Helius Medical Tech were among the top gainers, with stock prices increasing by 71.1%, 69.52%, and 55.04% respectively. On the losing side, BioVie, First Wave BioPharma, and Sunshine Biopharma saw declines of 46.0%, 29.44%, and 21.49%. Notably, 89bio and Akili released their Q4 earnings reports two days ago, influencing their stock movements.
March 04, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ainos shares moved upwards by 69.52% to $1.78, with a market value of $8.3 million.
Ainos' substantial pre-market gain indicates strong investor interest, possibly driven by favorable news or market trends benefiting the healthcare sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
89bio shares rose 38.66% to $17.5, with a market cap of $1.6 billion following their Q4 earnings report.
The positive movement in 89bio's stock price post-Q4 earnings suggests the market reacted favorably to the company's financial performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 95
POSITIVE IMPACT
Helius Medical Tech shares increased by 55.04% to $7.07, with a market value of $6.2 million.
The significant rise in Helius Medical Tech's stock price could reflect positive market reception to recent company achievements or broader sector trends.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Quoin Pharmaceuticals stock rose 71.1% to $4.74, with a market value of $4.6 million.
The significant pre-market increase in Quoin Pharmaceuticals' stock price suggests positive investor sentiment, potentially due to recent company developments or market conditions favoring healthcare stocks.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Akili stock decreased by 10.06% to $0.31, with a market value of $24.6 million after their Q4 earnings release.
Akili's stock price decline following the Q4 earnings announcement indicates the market may have had expectations that were not met by the reported results.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 95
NEGATIVE IMPACT
BioVie stock declined by 46.0% to $1.02, with a market value of $40.6 million.
BioVie's significant pre-market decline may indicate negative investor sentiment or reactions to recent company news or unfavorable market conditions.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90